JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37

Immunovant, Inc. (NASDAQ:IMVT) is one of the best biotech stocks with high potential. On September 30, JPMorgan analyst Brian Cheng lowered the firm’s price target on Immunovant, Inc. (NASDAQ:IMVT) to $33 from $37 while keeping an Overweight rating on the shares.

Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings?

Immunovant, Inc. (NASDAQ:IMVT) reported that its cash and cash equivalents totaled approximately $598.9 million in the quarter ending June 30, 2025, providing runway for announced indications through GD readout expected in 2027.

Immunovant, Inc. (NASDAQ:IMVT) develops treatments for autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402. Both are novel antibodies targeting the neonatal fragment crystallizable receptor (FcRn).

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.